See You This Afternoon at “Computing in the Age of the $1,000 Genome”

What will your doctor be able to tell you when your entire genome can be sequenced in an afternoon for $1,000 or less? Who out there in the business world has a handle on how to make this data useful? Will it actually help our society improve health and wellness?

I’m getting my game face on for a sold-out event we’re hosting this afternoon in Seattle called “Computing in the Age of the $1,000 Genome.” Registration for this half-day forum starts at around 1:15 pm, and the program will get going at 2 pm. As usual at Xconomy events, we’ll have networking before and after we hear from our all-star cast of speakers. The event will be at Swedish Medical Center’s Cherry Hill campus, Pinard Auditorium, 550 17th Avenue in Seattle.

Here’s a reminder of who’s coming to join the conversation. See you over there.

Leroy Hood, the co-founder and president of the Institute for Systems Biology, Seattle

Cliff Reid, co-founder and CEO, Mountain View, CA-based Complete Genomics

Eric Schadt, chief scientific officer, Menlo Park, CA-based Pacific Biosciences

Jim Karkanias, senior director, applied research and technology, Microsoft Health Solutions, Redmond, WA

Deepak Singh, senior business development manager, Amazon Web Services, Seattle

Rowan Chapman, partner, Menlo Park, CA-based Mohr Davidow Ventures

Andreas Sundquist, co-founder and CEO, Palo Alto, CA-based DNANexus

Ilya Kupershmidt, co-founder and VP of products, Cupertino, CA-based NextBio

Rob Arnold, president, Seattle-based Geospiza

Tim Hunkapiller, Seattle-based consultant, Life Technologies

Paul Rutherford, chief technology officer, Isilon Storage Division, EMC, Seattle

Bob Nelsen, managing director, Arch Venture Partners, Seattle

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.